Study of emapalumab for low blood counts after CAR T-cell therapy
Treatments studied
Part of Blood & lymphatic clinical trials.
This study tests a drug called emapalumab to help people whose blood counts stay low for weeks after CAR T-cell therapy for certain types of lymphoma. The goal is to see if the drug can help the body recover normal blood cell production.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had a type of CAR T-cell therapy (like axi-cel, tisa-cel, or liso-cel) for your lymphoma.
- Between 30 and 90 days after that therapy, you have low blood counts that are moderate to severe (low white blood cells, low platelets, or low hemoglobin).
- You are at least 18 years old.
- You are able to get out of bed and take care of yourself most of the day (ECOG performance status 0, 1, or 2).
- Your kidneys, liver, and oxygen levels are working well enough based on standard blood tests and a breathing test.
- You agree to use birth control (if applicable) and to have bone marrow biopsies before and after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if the drug emapalumab can help prevent toxic side effects often caused by CAR-T cell therapy. It is for adults with certain types of large B-cell lymphoma that have not responded to or returned after initial treatment.
This trial tests if umbilical cord stem cells can help restore low blood counts in people with leukemia, lymphoma, or myeloma who still have low blood cell levels three weeks after CAR-T therapy. It aims to improve recovery and reduce infection or bleeding risks.
This trial tests if a single dose of umbilical cord blood cells can help patients whose blood counts stay dangerously low after CAR-T or antibody therapy. It aims to reduce the need for transfusions and improve recovery.
This trial tests if giving back your own stored stem cells can help restore low blood cell counts that persist or develop 30 to 90 days after CAR-T therapy for multiple myeloma.
This trial tests if the drug epcoritamab can help people with B-cell lymphoma whose cancer showed only a partial response 30 days after CAR-T cell therapy. It compares epcoritamab to simply monitoring the condition.
This trial tests giving patients their own stored stem cells after CAR-T therapy to help recover low blood counts. It is for people with B-cell non-Hodgkin lymphoma whose blood counts are still low after CAR-T and who have a stable response to treatment.
Hear when a new Cytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.